Stevanato Group S.p.A. (STVN)
$
23.46
+1.06 (4.52%)
Key metrics
Financial statements
Free cash flow per share
-0.2350
Market cap
5.3 Billion
Price to sales ratio
4.6058
Debt to equity
0.2969
Current ratio
1.7872
Income quality
1.1504
Average inventory
267.9 Million
ROE
0.0971
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Stevanato Group S.p.A. is actively involved in the design, production, and distribution of integrated solutions tailored for the pharmaceutical and healthcare sectors. The company has reported an income before tax of $160,288,000.00 showcasing its pre-tax profitability, which reflects the efficacy of its operations. In addition to its core business activities, the net total of other income and expenses is -$854,000.00 highlighting the financial outcomes of non-core activities. Furthermore, the company incurred an interest expense of $7,425,000.00 which underscores its debt servicing obligations. Operationally, Stevanato Group S.p.A. reported selling, general, and administrative expenses of $116,570,000.00 indicating its overhead costs associated with daily operations. The EBITDA ratio is $0.22 providing insight into the company's operational efficiency and profitability. In terms of its market presence, the stock is considered affordable at $25.65 making it suitable for budget-conscious investors. The stock has an average trading volume of 335,823.00 indicating moderate liquidity, which can be beneficial for potential buyers. With a mid-range market capitalization of $6,402,276,111.00 the company is recognized as a steady performer in the market. Stevanato Group S.p.A. is a key player in the Medical - Instruments & Supplies industry, contributing significantly to the overall market landscape and reinforcing its relevance in the field. Additionally, it belongs to the Healthcare sector, where it drives innovation and growth through its diverse range of products and services.
Is Stevanato Group S.p.A. (STVN) a good investment?
Investing in Stevanato Group S.p.A. (STVN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bullish outlook. Always conduct your own research before investing.
What is Stevanato Group S.p.A. (STVN)'s stock forecast?
Analysts predict Stevanato Group S.p.A. stock to fluctuate between $17.12 (low) and $28 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Stevanato Group S.p.A.'s market capitalization?
As of 2025-08-29, Stevanato Group S.p.A.'s market cap is $6,402,276,111, based on 272,901,795 outstanding shares.
How does Stevanato Group S.p.A. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Stevanato Group S.p.A. has a Lower Market-Cap, indicating a difference in performance.
Does Stevanato Group S.p.A. pay dividends?
Stevanato Group S.p.A. pays dividends. The current dividend yield is 0.26%, with a payout of $0.06 per share.
How can I buy Stevanato Group S.p.A. (STVN) stock?
To buy Stevanato Group S.p.A. (STVN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for STVN. Place an order (Market, Limit, etc.).
What is the best time to invest in Stevanato Group S.p.A.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Stevanato Group S.p.A. perform in the last earnings report?
Revenue: $1,104,036,000 | EPS: $0.43 | Growth: -21.82%.
Where can I find Stevanato Group S.p.A.'s investor relations reports?
Visit https://www.stevanatogroup.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Stevanato Group S.p.A.?
You can explore historical data from here
What is the all-time high and low for Stevanato Group S.p.A. stock?
All-time high: $36.30 (2023-08-09) | All-time low: $13.36 (2022-05-10).
What are the key trends affecting Stevanato Group S.p.A. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Stevanato Group (STVN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.1 per share a year ago.
businesswire.com
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2025. Second Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 8% to €280.0 million, and high-value solutions represented 42% of total revenue. Gross profit margin increased 210.
zacks.com
Stevanato (STVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
Stevanato (STVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
businesswire.com
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2025 on Tuesday, August 5, 2025, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, August 5, 2025, to discuss.
seekingalpha.com
The new facility in the U.S. expects to generate €500 million in annual revenues by 2028. The global drug containment solution market is expected to grow at an 8% CAGR from 2024 to 2030. In this market, Stevanato has a competitive advantage. Stevanato's PP&E has increased by 304.61% between 2018 and Q1 2025, indicating the significant investment that the company has dedicated to expanding its operations.
seekingalpha.com
Q1 results exceeded expectations, driven by strong Biopharmaceutical and Diagnostic Solutions growth and margin expansion from scaling new facilities. 2025 guidance was reaffirmed despite FX headwinds and Engineering division weakness. High-value products continue to support a robust profit outlook and with a positive sales guidance, we confirm our buy rating.
seekingalpha.com
Stevanato Group S.p.A. (NYSE:STVN ) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Lisa Miles - SVP & Investor Relations Franco Stevanato - Chairman & Chief Executive Officer Marco Dal Lago - Chief Financial Officer Conference Call Participants Matt Larew - William Blair Paul Knight - KeyBanc Michael Ryskin - Bank of America David Windley - Jefferies Tejas Savant - Morgan Stanley Steven McLaurin Etoch - Stephens Inc Patrick Donnelly - Citi Doug Schenkel - Wolfe Research Operator Good afternoon.
zacks.com
Stevanato Group (STVN) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.09 per share a year ago.
businesswire.com
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2025. First Quarter 2025 Highlights (comparisons to prior-year period) Revenue for the first quarter of 2025 increased 9% to €256.6 million, and high-value solutions represented 43% of total revenue. Gross.
See all news
